| Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions Y Jamilloux, T Henry, A Belot, S Viel, M Fauter, T El Jammal, T Walzer, ... Autoimmunity reviews 19 (7), 102567, 2020 | 706 | 2020 |
| Adult-onset Still's disease M Gerfaud-Valentin, Y Jamilloux, J Iwaz, P Sève Autoimmunity reviews 13 (7), 708-722, 2014 | 596 | 2014 |
| Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents? P Sève, C Dumontet The lancet oncology 9 (2), 168-175, 2008 | 405 | 2008 |
| Class III β-tubulin expression in tumor cells predicts response and outcome in patients with non–small cell lung cancer receiving paclitaxel P Seve, J Mackey, S Isaac, O Tredan, PJ Souquet, M Perol, R Lai, ... Molecular Cancer Therapeutics 4 (12), 2001-2007, 2005 | 346 | 2005 |
| IgG4-related systemic disease: features and treatment response in a French cohort: results of a multicenter registry M Ebbo, L Daniel, M Pavic, P Sève, M Hamidou, E Andres, S Burtey, ... Medicine 91 (1), 49-56, 2012 | 288 | 2012 |
| Expression of class III β-tubulin is predictive of patient outcome in patients with non–small cell lung cancer receiving Vinorelbine-based chemotherapy P Sève, S Isaac, O Trédan, PJ Souquet, Y Pachéco, M Pérol, ... Clinical Cancer Research 11 (15), 5481-5486, 2005 | 288 | 2005 |
| Adult-onset still disease: manifestations, treatment, outcome, and prognostic factors in 57 patients M Gerfaud-Valentin, D Maucort-Boulch, A Hot, J Iwaz, J Ninet, I Durieu, ... Medicine 93 (2), 91-99, 2014 | 281 | 2014 |
| Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine A Mathian, M Mahevas, J Rohmer, M Roumier, F Cohen-Aubart, ... Annals of the rheumatic diseases 79 (6), 837-839, 2020 | 272 | 2020 |
| Thymoma associated with autoimmune diseases: 85 cases and literature review C Bernard, H Frih, F Pasquet, S Kerever, Y Jamilloux, F Tronc, B Guibert, ... Autoimmunity reviews 15 (1), 82-92, 2016 | 270 | 2016 |
| COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study J Avouac, E Drumez, E Hachulla, R Seror, S Georgin-Lavialle, ... The Lancet Rheumatology 3 (6), e419-e426, 2021 | 254 | 2021 |
| Chemoresistance in non-small cell lung cancer P Sève, C Dumontet Current Medicinal Chemistry-Anti-Cancer Agents 5 (1), 73-88, 2005 | 237 | 2005 |
| Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: Fundamentals Of Care for UveitiS (FOCUS) initiative AD Dick, JT Rosenbaum, HA Al-Dhibi, R Belfort Jr, AP Brézin, SP Chee, ... Ophthalmology 125 (5), 757-773, 2018 | 235 | 2018 |
| Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients S Georgin‐Lavialle, B Terrier, AF Guedon, M Heiblig, T Comont, E Lazaro, ... British Journal of Dermatology 186 (3), 564-574, 2022 | 230 | 2022 |
| Sarcoidosis: a clinical overview from symptoms to diagnosis P Sève, Y Pacheco, F Durupt, Y Jamilloux, M Gerfaud-Valentin, S Isaac, ... Cells 10 (4), 766, 2021 | 229 | 2021 |
| JAK inhibitors for the treatment of autoimmune and inflammatory diseases Y Jamilloux, T El Jammal, L Vuitton, M Gerfaud-Valentin, S Kerever, ... Autoimmunity reviews 18 (11), 102390, 2019 | 227 | 2019 |
| Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: multicenter study of 124 patients H Vallet, S Riviere, A Sanna, A Deroux, G Moulis, O Addimanda, ... Journal of autoimmunity 62, 67-74, 2015 | 221 | 2015 |
| Class III β-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non–small cell lung cancer: analysis of NCIC JBR. 10 P Seve, R Lai, K Ding, T Winton, C Butts, J Mackey, C Dumontet, ... Clinical cancer research 13 (3), 994-999, 2007 | 220 | 2007 |
| The role of 2‐deoxy‐2‐[F‐18] fluoro‐D‐glucose positron emission tomography in disseminated carcinoma of unknown primary site P Sève, C Billotey, C Broussolle, C Dumontet, JR Mackey Cancer 109 (2), 292-299, 2007 | 208 | 2007 |
| The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer LP Jordheim, P Sève, O Trédan, C Dumontet The lancet oncology 12 (7), 693-702, 2011 | 205 | 2011 |
| Therapeutic options in VEXAS syndrome: insights from a retrospective series E Bourbon, M Heiblig, M Gerfaud Valentin, T Barba, CA Durel, JC Lega, ... Blood, The Journal of the American Society of Hematology 137 (26), 3682-3684, 2021 | 202 | 2021 |
